Johnson & Johnson
Medical Device R&D and Manufacturer
Shockwave Medical
Cardiovascular Disease Treatment Device Developer
Sinopep
Developer, Manufacturer, and Distributor of Peptides and Small-Molecule Chemical Drugs
Walvax
Human Vaccine Research and Development, Manufacturer
Bio-Thera：Received the "Drug Registration Certificate" for tocilizumab injection issued by the National Medical Products Administration.
Yuan Dong Biotech:The product Butorphanol Tartrate Injection has received the "Drug Registration Certificate" issued by the National Medical Products Administration.
Sinopep Allsino Bio Pharmaceutical Co.,ltd.Announcement of Q1 2024 Earnings Forecast: Net Profit Attributable to Shareholders of RMB 55 million to RMB 70 million, an Increase of 161.74% to 233.13% Year-over-Year
BuChang Pharmaceutical:Shandong Danhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has received the "Notice of GMP Compliance Inspection for Pharmaceuticals" issued by the Shandong Provincial Drug Administration.
Meihao Medical:Proposed to use its own funds to repurchase company shares through centralized bidding. The repurchase price will not exceed 31.88 yuan per share, and the repurchase amount will be no less than 50 million yuan and no more than 100 million yuan.
Poly Pharm:Announcement on the Marketing Authorization of Daptomycin for Injection Granted by the Federal Institute for Drugs and Medical Devices (BfArM) in Germany
Fujian Cosunter Pharmaceutical Co.,Ltd.:Hepatitis B Core Protein Inhibitor GST-HG141 (Generic Name: Nericocevir) Receives U.S. Patent Notice of Allowance and Australian Patent Certificate
Tianyu Pharmaceutical Co., Ltd.:Received the "Drug Registration Certificate" for Ticagrelor Tablets issued by the National Medical Products Administration.
Walvax:Received the Phase III Immunogenicity Bridging Clinical Study Report for the mRNA vaccine targeting the SARS-CoV-2 variant strain (Omicron XBB.1.5), code name: RQ3033. The report shows that the Phase III immunogenicity bridging clinical trial results of this vaccine have comprehensively met the pre-set objectives, demonstrating good efficacy and safety.
Huaren Pharmaceutical Co.,Ltd.:Received the "Medical Device Registration Certificate" for the "Disposable Infusion Port Disinfection Cap" approved and issued by the Shandong Provincial Drug Administration.
$13.1 Billion! Johnson & Johnson Acquires Shockwave Medical
On April 5, Johnson & Johnson announced that it had reached a definitive agreement with Shockwave Medical to acquire all outstanding shares of the latter in an all-cash transaction at $335 per share, valuing the deal at approximately $13.1 billion. The transaction is expected to close by mid-2024. Shockwave Medical is the leading and only provider of innovative intravascular lithotripsy (IVL) technology, a minimally invasive, catheter-based treatment for calcified arterial lesions, and the only technology capable of treating intimal and medial calcification. IVL helps restore blood flow by using sonic pressure waves to crack calcified lesions and is typically used in conjunction with stent placement. The acquisition of Shockwave Medical further strengthens Johnson & Johnson’s position in the cardiovascular interventional treatment field within its medical technology division and accelerates its move into high-growth markets.
Pan-Tumor Breakthrough: DS-8201 Receives FDA Approval for Treatment of HER2-Positive Solid Tumors
On April 5, the FDA granted accelerated approval to Trastuzumab Deruxtecan for the treatment of unresectable or metastatic HER2-positive solid tumors, marking a breakthrough for ADC drugs across various tumor types. This accelerated approval came nearly two months ahead of the PDUFA date of May 30. Since its market launch, DS-8201 has achieved continuous clinical breakthroughs in frontline therapy, HER2-low breast cancer, non-small cell lung cancer, gastric cancer, and HER2-positive solid tumors, with sales also rising steadily, reaching $2.476 billion in 2023.
New Pancreatic Cancer Therapy Significantly Extends Patient Survival, Candel Therapeutics' Stock Soars 281%
On April 4, Candel Therapeutics announced the latest Phase II study data on CAN-2409 in combination with valacyclovir and chemotherapy for borderline resectable pancreatic cancer. As of the data cutoff date of March 29, 2024, the median overall survival (mOS) was significantly prolonged in patients receiving CAN-2409 combination therapy (total n=13), with an estimated mOS of 28.8 months compared to just 12.5 months in the control group. Importantly, as of the data cutoff, 4 out of 7 patients in the CAN-2409 treatment group were still alive, including 2 patients who survived over 50 months post-enrollment, while only 1 out of 6 patients in the control group receiving chemoradiotherapy remained alive, with a survival time of 50.6 months. Following this positive study data, Candel's stock price surged by 280.95%.
Industry Communication and Exchange
